hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8482-8490

  Nordh, Stina ^a   Ansari, Daniel ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Gemcitabine; hENT1; Pancreatic cancer; Predictive; Survival

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; TUMOR MARKER; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; SLC29A1 PROTEIN, HUMAN;

CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RESPONSE; COCHRANE LIBRARY; DISEASE SPECIFIC SURVIVAL; EMBASE; MEDLINE; ANALOGS AND DERIVATIVES; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904395417     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8482     Document Type: Review

References (31)

1. Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-74. e1-6 [PMID: 22705007 DOI: 10.1053/j.gastro.2012.06.006]
2. Kawada N, Uehara H, Katayama K, Nakamura S, Takahashi H, Ohigashi H, Ishikawa O, Nagata S, Tomita Y. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepatobiliary Pancreat Sci 2012; 19: 717-722 [PMID: 22426593 DOI: 10.1007/s00534-012-0514-x]
3. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-2919 [PMID: 19318496 DOI: 10.1158/1078-0432.CCR-08-2080]
4. Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology 2009; 77: 217-223 [PMID: 19729980 DOI: 10.1159/000236022]
5. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, Sebastiano PD. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19: 1644-1662 [PMID: 22012027 DOI: 10.1245/s10434-011-2110-8]
6. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, Sandvold ML. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009; 44: 782-786 [PMID: 19214867 DOI: 10.1080/00365520902745039]
7. García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluoro-deoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008 [PMID: 14581375] (Pubitemid 37323307)
8. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010; 12: 807-817 [PMID: 20927319]
9. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-6961 [PMID: 15501974 DOI: 10.1158/1078-0432.CCR-04-0224] (Pubitemid 39383046)
10. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-3935 [PMID: 16585222 DOI: 10.1158/0008-5472.CAN-05-4203]
11. Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res 2009; 28: 83 [PMID: 19531250 DOI: 10.1186/1756-9966-28-83]
12. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195 [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067]
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012 [PMID: 19631508 DOI: 10.1016/j.jclinepi.2009.06.005]
14. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216 [PMID: 22675273 DOI: 10.1371/journal.pmed.1001216]
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]
16. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116: 5325-5335 [PMID: 20665488 DOI: 10.1002/cncr.25282]
17. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-329 [PMID: 20028759 DOI: 10.1158/1078-0432.CCR-09-1555]
18. Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 2011; 117: 3126-3134 [PMID: 21264835 DOI: 10.1002/cncr.25883]
19. Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann Surg Oncol 2012; 19 Suppl 3: S646-S655 [PMID: 22086444 DOI: 10.1245/s10434-011-2140-2]
20. Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 2008; 99: 760-767 [PMID: 18728667 DOI: 10.1038/sj.bjc.6604528]
21. Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 2012; 19 Suppl 3: S558-S564 [PMID: 21913012 DOI: 10.1245/s10434-011-2054-z]
22. Murata Y, Hamada T, Kishiwada M, Ohsawa I, Mizuno S, Usui M, Sakurai H, Tabata M, Ii N, Inoue H, Shiraishi T, Isaji S. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci 2012; 19: 413-425 [PMID: 21898089 DOI: 10.1007/s00534-011-0440-3]
23. Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013; 153: 565-575 [PMID: 23253379 DOI: 10.1016/j.surg.2012.10.010]
24. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets 2011; 11: 123-129 [PMID: 20578980]
25. Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg 2012; 256: 288-296 [PMID: 22580938 DOI: 10.1097/SLA.0b013e3182536a42]
26. Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H, Ohashi Y, Hara I. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int 2011; 108: E110-E116 [PMID: 21166756 DOI: 10.1111/j.1464-410X.2010.09932.x]
27. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 2007; 256: 112-119 [PMID: 17658213 DOI: 10.1016/j.canlet.2007.06.012] (Pubitemid 47333332)
28. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 [PMID: 9196156] (Pubitemid 27251144)
29. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026 [PMID: 18319412 DOI: 10.1001/jama.299.9.1019] (Pubitemid 351347058)
30. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277 [PMID: 17227978 DOI: 10.1001/jama.297.3.267] (Pubitemid 46143304)
31. Ansari D, Tingstedt B, Andersson R. Pancreatic cancer - cost for overtreatment with gemcitabine. Acta Oncol 2013; 52: 1146-1151 [PMID: 23244671 DOI: 10.3109/0284186X.2012.744140]